Margaret von Mehren1, Michael C Heinrich2, Hongliang Shi3, Sergio Iannazzo3, Raymond Mankoski3, Saša Dimitrijević3, Gerard Hoehn3, Silvia Chiroli3, Suzanne George4. 1. Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA. Margaret.vonMehren@fccc.edu. 2. Division of Hematology and Medical Oncology, Portland VA Health Care System and Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. 3. Blueprint Medicines Corporation, Cambridge, MA, USA. 4. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST). METHODS: This retrospective analysis compared efficacy of avapritinib in patients enrolled in the NAVIGATOR phase 1 trial (NCT02508532) with the efficacy of other tyrosine kinase inhibitors (TKIs) in patients with unresectable/metastatic PDGFRA D842V-mutant GIST enrolled in a retrospective natural history study (Study 1002). The primary endpoint was overall survival (OS) from the start of reference treatment (avapritinib for NAVIGATOR patients or first-line TKI for treatment of unresectable/metastatic GIST for Study 1002 patients); the secondary endpoint was progression-free survival (PFS). Adjusted Kaplan-Meier survival curves were compared by Cox regression. RESULTS: Fifty-six (NAVIGATOR) and 19 (Study 1002) patients with PDGFRA D842V-mutant GIST were evaluated; of the 56 patients from NAVIGATOR, a subgroup of patients treated with either 300 mg (recommended phase 2 dose) or 400 mg (maximum tolerated dose) avapritinib starting dose (n = 38) were analyzed separately. Patient characteristics were adjusted for imbalances by propensity score between the study groups. Inverse probability of treatment weighting-adjusted Kaplan-Meier analysis of OS showed median OS was not reached for NAVIGATOR patients treated with any of the avapritinib doses tested and was 12.6 months for Study 1002 patients; OS rate at 6/48 months was 100%/63% in NAVIGATOR and 56%/17% in Study 1002 (P = 0.0001). In the 300/400 mg subgroup, adjusted OS rates at 6/36 months were 100%/73 and 68%/20% in Study 1002 (P = 0.0016). Adjusted median PFS was 29.5 months in NAVIGATOR and 3.4 months in Study 1002. CONCLUSIONS: In this indirect, retrospective analysis, avapritinib demonstrated more durable survival outcomes compared with other TKIs in patients with unresectable/metastatic PDGFRA D842V-mutant GIST. TRIAL REGISTRATION: The NAVIGATOR trial was registered at ClinicalTrials.gov as per July 2015, Identifier: NCT02508532 .
BACKGROUND:Avapritinib, a potent inhibitor of KIT and platelet-derived growth factor receptor A (PDGFRA) tyrosine kinases, has demonstrated unprecedented clinical activity in PDGFRAD842V-mutant gastrointestinal stromal tumors (GIST). METHODS: This retrospective analysis compared efficacy of avapritinib in patients enrolled in the NAVIGATOR phase 1 trial (NCT02508532) with the efficacy of other tyrosine kinase inhibitors (TKIs) in patients with unresectable/metastatic PDGFRAD842V-mutant GIST enrolled in a retrospective natural history study (Study 1002). The primary endpoint was overall survival (OS) from the start of reference treatment (avapritinib for NAVIGATOR patients or first-line TKI for treatment of unresectable/metastatic GIST for Study 1002 patients); the secondary endpoint was progression-free survival (PFS). Adjusted Kaplan-Meier survival curves were compared by Cox regression. RESULTS: Fifty-six (NAVIGATOR) and 19 (Study 1002) patients with PDGFRAD842V-mutant GIST were evaluated; of the 56 patients from NAVIGATOR, a subgroup of patients treated with either 300 mg (recommended phase 2 dose) or 400 mg (maximum tolerated dose) avapritinib starting dose (n = 38) were analyzed separately. Patient characteristics were adjusted for imbalances by propensity score between the study groups. Inverse probability of treatment weighting-adjusted Kaplan-Meier analysis of OS showed median OS was not reached for NAVIGATOR patients treated with any of the avapritinib doses tested and was 12.6 months for Study 1002 patients; OS rate at 6/48 months was 100%/63% in NAVIGATOR and 56%/17% in Study 1002 (P = 0.0001). In the 300/400 mg subgroup, adjusted OS rates at 6/36 months were 100%/73 and 68%/20% in Study 1002 (P = 0.0016). Adjusted median PFS was 29.5 months in NAVIGATOR and 3.4 months in Study 1002. CONCLUSIONS: In this indirect, retrospective analysis, avapritinib demonstrated more durable survival outcomes compared with other TKIs in patients with unresectable/metastatic PDGFRAD842V-mutant GIST. TRIAL REGISTRATION: The NAVIGATOR trial was registered at ClinicalTrials.gov as per July 2015, Identifier: NCT02508532 .
Authors: Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson Journal: Eur J Cancer Date: 2006-04-18 Impact factor: 9.162
Authors: Philippe A Cassier; Elena Fumagalli; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Maria Debiec-Rychter; Jean-François Emile; Florence Duffaud; Javier Martin-Broto; Bruno Landi; Antoine Adenis; François Bertucci; Emmanuelle Bompas; Olivier Bouché; Serge Leyvraz; Ian Judson; Jaap Verweij; Paolo Casali; Jean-Yves Blay; Peter Hohenberger Journal: Clin Cancer Res Date: 2012-06-20 Impact factor: 12.531
Authors: Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Sheima Farag; Neeta Somaiah; Haesun Choi; Birthe Heeres; Wei-Lien Wang; Hester van Boven; Petra Nederlof; Robert Benjamin; Winette van der Graaf; Dirk Grunhagen; Pieter A Boonstra; Anna K L Reyners; Hans Gelderblom; Neeltje Steeghs Journal: Eur J Cancer Date: 2017-03-08 Impact factor: 9.162
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: N Gökbuget; M Kelsh; V Chia; A Advani; R Bassan; H Dombret; M Doubek; A K Fielding; S Giebel; V Haddad; D Hoelzer; C Holland; N Ifrah; A Katz; T Maniar; G Martinelli; M Morgades; S O'Brien; J-M Ribera; J M Rowe; A Stein; M Topp; M Wadleigh; H Kantarjian Journal: Blood Cancer J Date: 2016-09-23 Impact factor: 11.037
Authors: Jeffrey J Kooijman; Wilhelmina E van Riel; Jelle Dylus; Martine B W Prinsen; Yvonne Grobben; Tessa J J de Bitter; Antoon M van Doornmalen; Janneke J T M Melis; Joost C M Uitdehaag; Yugo Narumi; Yusuke Kawase; Jeroen A D M de Roos; Nicole Willemsen-Seegers; Guido J R Zaman Journal: Front Oncol Date: 2022-09-14 Impact factor: 5.738